-
Ozempic Is About to Be Old News
-
It’s the Age of Ozempic. Do We Need Weight Watchers Anymore?
-
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomized, double-blind, placebo-controlled, phase 3 trial
-
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
-
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial
-
https://x.com/DanielJDrucker/status/1673383917888348174
-
https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss-results
-
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial
-
https://x.com/FattyLiverA/status/1672144869886685189
-
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/
-
Could Danuglipron Be the Next Ozempic in Pill Form?
-
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial
-
https://x.com/AliceYYCheng/status/1673434959900717056
-
https://www.nature.com/articles/s42255-023-00811-0
-